Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK3 | O43781 | 5/20 | 0.69 |
| ▸ | GSK3B | P49841 | 4/20 | 0.65 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.59 |
| ▸ | TUBB | P07437 | 1/20 | 0.59 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.59 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.59 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.59 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.59 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.59 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.59 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.59 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.59 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.59 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.59 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.59 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.59 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.59 |
| ▸ | CLK1 | P49759 | 3/20 | 0.59 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.59 |
| ▸ | DYRK2 | Q92630 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2787533 | 1.00 | DYRK3 (0.69) | DYRK3GSK3BTUBB4ATUBBTUBA3C | |
| SCHEMBL13196777 | 1.00 | DYRK3 (0.69) | DYRK3GSK3BTUBB4ATUBBTUBA3C | |
| SCHEMBL2787898 | 0.89 | CLK1 (0.73) | DYRK3GSK3BCLK1DYRK1ADYRK2 | |
| SCHEMBL2787896 | 0.89 | CLK1 (0.73) | DYRK3GSK3BCLK1DYRK1ADYRK2 | |
| SCHEMBL13196791 | 0.89 | CLK1 (0.73) | DYRK3GSK3BCLK1DYRK1ADYRK2 | |
| SCHEMBL13041816 | 0.85 | DYRK3 (0.80) | DYRK3GSK3BTUBB4ATUBBTUBA3C | |
| SCHEMBL2786264 | 0.85 | DYRK3 (0.80) | DYRK3GSK3BTUBB4ATUBBTUBA3C | |
| SCHEMBL2786265 | 0.85 | DYRK3 (0.80) | DYRK3GSK3BTUBB4ATUBBTUBA3C | |
| SCHEMBL13078042 | 0.85 | DYRK3 (0.80) | DYRK3GSK3BTUBB4ATUBBTUBA3C | |
| SCHEMBL3390280 | 0.84 | DYRK3 (0.78) | DYRK3GSK3BTUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767701-B2 | protein serine/threonine kinase inhibitors such as 2-(2-Chloro-5-fluoro-phenylimino)-5-(2,3-dihydro-benzo[1-6]dioxin-6-ylmethylene)-thiazolidin-4-one, used for treating autoimmune diseases, HIV, cancer, anemia myelodysplastic syndrome and thrombocytopenia | GLAXOSMITHKLINE LLC (US) | 2010-08-03 | — | — | US | claimed |
| US-20090023742-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-01-22 | — | — | US | claimed |
| EP-1993535-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-11-26 | — | — | EP | claimed |
| EP-1567112-B1 | THIAZOLIDIN-4-ONES FOR INHIBITING hYAK3 PROTEINS | SMITHKLINE BEECHAM CORP (US) | 2008-10-15 | — | — | EP | claimed |
| WO-2007103754-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | claimed |
| US-20060293338-A1 | Novel chemical compounds | GLAXOSMITHKLINE LLC | 2006-12-28 | — | — | US | claimed |
| EP-1567112-A4 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2006-11-15 | — | — | EP | claimed |
| EP-1567112-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-31 | — | — | EP | claimed |
| WO-2004047760-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-10 | — | — | WO | claimed |
| US-7767701-B2 | protein serine/threonine kinase inhibitors such as 2-(2-Chloro-5-fluoro-phenylimino)-5-(2,3-dihydro-benzo[1-6]dioxin-6-ylmethylene)-thiazolidin-4-one, used for treating autoimmune diseases, HIV, cancer, anemia myelodysplastic syndrome and thrombocytopenia | GLAXOSMITHKLINE LLC (US) | 2010-08-03 | — | — | US | disclosed |
| US-20090023742-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-01-22 | — | — | US | disclosed |
| EP-1993535-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-11-26 | — | — | EP | disclosed |
| EP-1567112-B1 | THIAZOLIDIN-4-ONES FOR INHIBITING hYAK3 PROTEINS | SMITHKLINE BEECHAM CORP (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007103754-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20060293338-A1 | Novel chemical compounds | GLAXOSMITHKLINE LLC | 2006-12-28 | — | — | US | disclosed |
| EP-1567112-A4 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2006-11-15 | — | — | EP | disclosed |
| EP-1567112-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004047760-A2 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293338-A1 | Novel chemical compounds | HIPK3, HIPK1, HIPK4 | DYRK3 1446/4885GSK3B 503/4885TUBB4A 1155/4885 |
| US-20090023742-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | PIK3CA, BTK, PI4KA | DYRK3 1357/4885GSK3B 101/4885TUBB4A 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.